Clinical research blog
Explore our blog for insights into the big questions in precision medicine and clinical research.
Clinical trials play a crucial role in the development of pharmaceutical and biotech products. However, unforeseen challenges can arise during the trial process, potentially jeopardising the integrity and outcomes of the study. As a recent Applied Clinical Trial article noted, “while drug discovery is mostly about science, drug development is rich with, and risked by, human drama.”
Data security and privacy are critical considerations in the biotech industry, especially for companies working in genetics.
Genomics-based drug discovery offers great potential for the development of targeted therapies that can offer new and better treatment options for patients. By utilising genetic and biomarker information, this approach allows us to gain insights into the fundamental causes of diseases. But this growing field is not without its challenges.
Last week, our team had the privilege of attending the European Association for the Study of the Liver (EASL) conference, where groundbreaking advancements in liver research were unveiled. The conference provided an exceptional platform for experts and researchers to exchange knowledge and foster collaboration in the field of liver disease. In discussions with fellow conference-goers, our team identified several noteworthy themes emerging as key areas of interest. These included the pivotal role of genetics, particularly the PNPLA3 gene, in driving liver fibrosis in NAFLD/MASLD, the significance of AATD SERPINA 1 - PiZZ genotype pathogenicity, and the nomenclature change in NASH and MASH. Here, we will explore these developments, shedding light on the implications they hold for the future of liver disease research and patient care.
At Sano, we know that measuring and optimising data is the key to successful execution of clinical trials. That’s why we’ve put together a three-page report on key strategies to measure and optimise your data in a way that streamlines your operations. In it, we explore the significance of data collection and integration, real-time analytics, performance metrics, and predictive modelling in the world of clinical trials. Download below to learn more!
This webinar, hosted by Lindsey Wahlstrom-Edwards, Partnerships Lead for Sano Genetics, and featuring Wayne Eskridge and Dr. Neeraj Mistry from the Fatty Liver Foundation, was an informative session on the genetics and lifestyle factors that contribute to metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
Patient engagement has always been a cornerstone of successful clinical trials. It's a dynamic process that begins long before the trial and continues well after its conclusion. By fostering a strong relationship between researchers and patients, patient engagement can help improve enrollment, boost retention rates, improve the accuracy of data collected, and ensure the trial's overall success. This blog outlines the importance of patient engagement, then introduces the concept of a “Virtual Waiting Room” through which clinical trial sponsors can engage patients throughout the stages and phases of a study.
In the rapidly evolving landscape of clinical trials, technology continues to reshape and optimise various aspects of the research process. One area where digital innovation has made significant strides is in the realm of electronic consent, or e-consent. This approach to obtaining participant consent leverages the power of digital platforms to streamline and enhance the enrollment experience. By eliminating cumbersome paper-based processes, e-consent makes the consent process more efficient, accessible, and user-friendly. Participants can conveniently review and provide consent remotely, overcoming geographical barriers and expanding the reach of clinical trials. Additionally, interactive features and multimedia elements incorporated in e-consent platforms foster better participant comprehension, empowering individuals to make informed decisions about their participation.
Recently, our team was honoured to attend the World Orphan Drug Congress USA in Boston. The event brought together key stakeholders, experts, and industry leaders in the field of orphan drugs and rare diseases, and provided a platform for collaboration, knowledge sharing, and innovation in the pursuit of improved treatments for rare diseases. The Sano team enjoyed the insightful keynote presentations, interactive panel discussions, and valuable networking opportunities.
Clinical trials are crucial for advancing medical knowledge, developing life-saving treatments, and improving healthcare outcomes. However, for much of history, the participation of women in clinical trials has been limited or non-existent. In this blog, we explore the history of women's inclusion in clinical trials, highlighting the challenges faced and the progress made over time.